Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study
- 21 April 2023
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (10) , 1862-1868
Abstract
Introduction Omalizumab is used for the treatment of severe allergic asthma. Objective The aim of this study was to evaluate the clinical features and laboratory data of patients with severe allergic asthma classified as super-responder or non super-responder to omalizumab. Methods Comparisons were made of the laboratory data and clinical features of patients with severe allergic asthma. Patients who had no asthma exacerbation, no oral corticosteroid (OCS) use, asthma control test (ACT) score >20 and forced expiratory volume in 1 second (FEV1) >80% were considered super-responder after omalizumab. Results A total of 90 patients were included in the study, comprising 19 (21.1%) males. The age at onset of asthma, allergic rhinitis rate, number of endoscopic sinus surgeries (ESS), intranasal corticosteroid (INS) use, baseline FEV 1 (%) and ACT score were significantly higher in the omalizumab super-responder group (p = 0.013, p = 0.015, p = 0.002, p = 0.001, p = 0.001 and p < 0.001, respectively). The duration of asthma, rate of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), regular use of OCS, baseline eosinophil count and eosinophil/lymphocyte ratio were significantly higher in the omalizumab non super-responder group (p = 0.015, p < 0.001, p = 0.004, p < 0.001 and p < 0.001, respectively). Blood eosinophil count (AUC: 0.187, p < 0.001), Eosinophil/Lymphocyte ratio (AUC: 0.150, p < 0.001) and FEV1 (%) (AUC:0.779, p = 0.001) were determined to have diagnostic value in predicting the treatment response to omalizumab of patients with severe allergic asthma. Conclusion High blood eosinophil levels, CRSwNP, and low pre-treatment lung capacity may affect omalizumab treatment response in patients with severe allergic asthma. These results should be supported by further multicentre real-life studies.Keywords
This publication has 21 references indexed in Scilit:
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaAllergy, 2020
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaAllergy, 2020
- Severe asthma phenotypes in patients controlled with omalizumab: A real-world studyRespiratory Medicine, 2019
- Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical historyJournal of Asthma and Allergy, 2018
- Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life studyPostgraduate Medicine, 2017
- Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteriaClinical & Experimental Allergy, 2013
- The skin prick test – European standardsClinical and Translational Allergy, 2013
- Omalizumab: Anti-IgE Therapy in AllergyCurrent Allergy and Asthma Reports, 2011
- Standardisation of spirometryEuropean Respiratory Journal, 2005